藥明生物德國基地計劃擴大產能 新增預充針製劑灌裝生產線

Swipe Left For English News

德國勒沃庫森

2024年11月13日

全球領先的合同研究、開發和生產（CRDMO）服務公司藥明生物（WuXi Biologics, 2269.HK）今日宣佈，公司將擴大德國勒沃庫森基地產能，新建一條隔離器灌裝預充針生產線。

此次擴建將優化基地生產佈局，為多產品的CRDMO服務提供更高效的解決方案。該新增產線可以為多種規格的預充針進行灌裝（1毫升、2.25毫升和3毫升），灌裝速度最快可達400支/分鍾，年產能超過1700萬支。目前德國勒沃庫森基地已有一條無菌灌裝和凍乾製劑生產線，年產能達1000萬瓶，擴建后將更靈活地服務於全球客户的多元化需求。該新增產線預計將在近期啟動建設，2026年達到GMP生產標準。

陳智勝

博士

藥明生物首席執行官

此次擴大德國產能將進一步滿足客户日益增長的製劑服務需求，特別是預充針。這也再次鞏固了我們全球雙廠戰略——確保物料多源採購和客户產品多地生產。作為全球醫藥企業值得信賴的合作伙伴和運營基地當地的重要貢獻方，我們致力於提供高效且具有成本效益的生物藥研究、開發和生產解決方案，賦能客户研發突破性療法，惠及廣大病患。

關於藥明生物

藥明生物（股票代碼：2269.HK）是一家全球領先的合同研究、開發和生產（CRDMO）公司。公司通過開放式、一體化生物製藥能力和技術賦能平臺，提供全方位的端到端服務，幫助合作伙伴發現、開發及生產生物藥，實現從概念到商業化生產的全過程，加速全球生物藥研發進程，降低研發成本，造福病患。

藥明生物在中國、美國、愛爾蘭、德國和新加坡擁有超過12000名員工。通過藥明生物的專業服務團隊，以及先進技術和精深洞見，公司為客户提供高效經濟的生物藥解決方案。截至2024年6月底，藥明生物幫助客户研發和生產的綜合項目高達742個，其中包括16個商業化生產項目（不包括新冠項目和非活躍項目）。

藥明生物將環境、社會和治理（ESG）視為業務發展和企業精神的重要組成部分，並致力於成為全球生物藥CRDMO領域的ESG領導者，例如應用更綠色環保的新一代生物製藥技術和能源等引領行業發展。公司成立了由首席執行官領導的ESG委員會，全面落實ESG戰略並踐行可持續性發展承諾。更多信息，請訪問：www.wuxibiologics.com。

業務垂詢        

info@wuxibiologics.com

媒體關係  

PR@wuxibiologics.com

WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line

Leverkusen, Germany, 

November 13, 2024

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it will enhance its drug product (DP) capabilities at the company's facility in Leverkusen, Germany, with a new sterile filling line for prefilled syringes (PFS) using isolator technology. 

Construction of the new line will optimize the design of the Leverkusen facility's manufacturing layout to be more efficient for multi-product CRDMO use. The new line, with its capability to handle multiple syringe sizes (1 ml, 2.25 ml, and 3 ml) at a filling rate of up to 400 syringes per minute, enables flexible GMP production of at least 17 million syringes every year. This will be in addition to the existing sterile filling and freeze-drying line that has an annual capacity of approximately ten million doses. Construction is scheduled to commence recently, with the goal of achieving GMP compliance by 2026.

Dr. Chris Chen

Chief Executive Officer

WuXi Biologics

The increased capacity in Germany will allow us to continue to meet growing client demand for DP services, especially for prefilled syringes. Such investments further demonstrate our commitment to the Global Dual Sourcing strategy that ensures materials can be sourced and products manufactured at multiple sites within the company's global network. As a trusted partner to global healthcare companies and a significant contributor to the local community, we are dedicated to providing efficient and cost-effective processes that enable our clients to bring breakthrough therapies to patients.

About 

WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2024, WuXi Biologics is supporting 742 integrated client projects, including 16 in commercial manufacturing (excluding  COVID CMO and non-COVID dormant CMO projects).

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities a an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com